.
MergerLinks Header Logo

New Deal


Announced

Mindray to acquire HyTest from Summa Equity for $665m.

Financials

Edit Data
Transaction Value£468m
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Finland

therapeutic antibodies

Cross Border

Single Bidder

Private Equity

Majority

Pending

Biotechnology

Friendly

Acquisition

Private

Synopsis

Edit

Mindray, a company that develops, manufactures, and markets medical devices, agreed to acquire HyTest, a manufacturer of scientifically created antibodies, from Summa Equity, a thematic investment companyб for $665m. "With the resources available from Mindray, we can further develop our capabilities to serve our customers and fulfill their needs for best-in-class reagents for developing reliable and sensitive immunoassays on various platforms," Juhana Rauramo, HyTest CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US